Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 1

Opinion

Video

March 21, 2025

Limitations and Challenges in Skin Cancer Staging Systems

Author(s):

An expert discusses the patient demographics and clinical features used in traditional staging and risk classification of melanoma and squamous cell carcinoma (SCC), examining how staging systems from organizations like the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) align in risk classification, the challenges of relying solely on clinical features for prognosis, and the importance of accurate risk staging in guiding treatment decisions for these cancers.

Now Viewing

Discuss the patient demographics and clinical features that are included in traditional staging and risk classification of melanoma and SCC.
Do the different staging systems, such as ones used by AJCC and NCCN, generally agree with regard to risk classification? Discuss some of the challenges with basing prognosis strictly on clinical features.
What is the importance of accurate risk staging? How do treatment guidelines for melanoma and SCC differ based on the patient’s risk profile?

Limitations and Challenges in Skin Cancer Staging Systems

EP: 1.Limitations and Challenges in Skin Cancer Staging Systems

EP: 2.Utility of Molecular Testing in Skin Cancer Risk Assessment

EP: 3.Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP: 4.Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma